14 results about "Leishmaniasis" patented technology

A first aspect of the invention relates to a method of treating or preventing tissue damage, or treating or preventing tissue destruction, in a subject, said method comprising administering to the subject a therapeutically or prophylactically effective amount of a soluble epoxide hydrolase (sEH) inhibitor. A further aspect of the invention relates to a method of treating or preventing leishmaniasis in a subject, said method comprising administering to the subject a therapeutically or prophylactically effective amount of a soluble epoxide hydrolase inhibitor.

The present invention provides therapeutic and / or prophylactic treatments against leishmaniasis in non-human mammals in need of such treatment, said treatments comprising administering oleyl phosphocholine to said non-human mammal. The invention also relates to veterinary (pharmaceutical) compositions adapted, suitable and / or intended for use in these treatments.

The invention relates to a process for obtaining an amphotericin B (AmB) formulation in liposomes containing dicetyl phosphate (DCP), based on incorporation of the drug into the membrane of preformed liposomes, combining the effects of pH on the solubility of amphotericin B and of temperature on the insertion of the drug into the liposome membrane. The technology also relates to use of the process and of the formulation for the manufacture of medicaments for the treatment of leishmaniasis and sporotrichosis, for oral or topical administration.

The present invention relates to use of boron derivatives as therapeutics in Leishmaniasis disease. The objective of the present invention relates to the use of sodium perborate tetrahydrate (SPT), which is almost completely effective on Leishmania parasites, but does not show toxicity in healthy cells, in antileishmanial therapy. Considering the methods and techniques which have been developed, the success achieved in the use of SPT and boron derivatives as therapeutics against Leishmaniasis observed within the scope of the invention lays the groundwork for treatments of other infectious diseases and enables the design and development of novel preventive and therapeutic methods. There is provided a novel treatment that can be an alternative to conventional drug therapies (such as amphotericin B antimonials) applied in the treatment of Leishmaniasis, which have difficult patient compliance due to side effects.

The present application provides a combination product for the treatment and / or prevention of infections caused by parasites of the genus Leishmania.

The current invention provides an improved process of the manufacture of pharmaceutical products comprising proteins, useful for the prevention or treatment of leishmaniasis. The pharmaceutical composition comprises a protein chimera Q, which is the product of a chimeric gene encoding the antigenic determinants of four proteins of Leishmania infantum.

The invention belongs to the technical field of microbiological detection, and particularly relates to a primer and a method for rapidly detecting leishmaniasis infection. The invention relates to a primer for rapidly detecting leishmaniasis infection. The primer comprises a forward external primer F3 and a reverse external primer F3, wherein the nucleotide sequence of the forward external primer F3 is as shown in SEQ ID NO.1; the nucleotide sequence of the reverse external primer B3 is as shown in SEQ ID NO. 2; the nucleotide sequence of the forward internal primer FIP is as shown in SEQ ID NO.3; the nucleotide sequence of the reverse internal primer BIP is as shown in SEQ ID NO. 4; the nucleotide sequence of the forward loop primer LF is as shown in SEQ ID NO.5; and the nucleotide sequence of the reverse loop primer LB is as shown in SEQ ID NO.6. According to the present invention, the reaction time is successfully controlled within 15-30 min through the optimization design of the primer sequence for detecting the leishmaniasis infection, and the method has advantages of simple operation, high sensitivity, strong specificity, and wide application prospect.

A first aspect of the invention relates to a method of treating or preventing tissue damage, or treating or preventing tissue destruction, in a subject, said method comprising administering to the subject a therapeutically or prophylactically effective amount of a soluble epoxide hydrolase (sEH) inhibitor. A further aspect of the invention relates to a method of treating or preventing leishmaniasis in a subject, said method comprising administering to the subject a therapeutically or prophylactically effective amount of a soluble epoxide hydrolase inhibitor.

The presentation invention relates to compounds of formula (I) and pharmaceutical compositions thereof. The compounds may be used to treat an infection, such as a parasitic infection or a bacterial infection. In some embodiments, the compounds may be used to treat leishmaniasis.

Diagnostic methods, systems, test strips, test kits, and other immunoassay materials are provided for the detection of antibodies to one or more specific parasites of veterinary and human concern in biological samples, including those that are responsible for Chagas disease (Trypanosoma cruzi), Leishmaniasis (Leishmania infantum), and Heartworm (Dirofilaria immitis).

The application relates to fumaric acid cocrystals of N-(4-fluoro-3-(6-(3-methylpyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl)-2,4-dimethyloxazol-5-carboxamide (Compound I) and X-ray amorphous complexes of Compound (I) and fumaric acid. The application also provides methods for their preparation; pharmaceutical compositions containing them; and their use in the treatment, prevention, inhibition, improvement, or eradication of the pathology and / or symptoms of a disease caused by a kinetoplastid parasite, such as leishmaniasis, human African trypanosomiasis, and Chagas disease.

The present invention relates to the use of boron derivatives as therapeutics in neuroinflammation caused by Leishmania parasites. The objective of the invention is to reduce cell viability on astrocytes infected with Leishmania infantum promastigotes and to use sodium perborate tetrahydrate (SPT), a boron derivative, as therapeutics against neuronal Leishmaniasis because it does not show any toxic effect on healthy cells. The experimental results demonstrates that SPT treatment causes a significant activity (reduction) on infection rate of C8-S astrocyte cells infected with L. infantum parasites by reducing the cellular toxicity on astrocytes and that oxidative stress on infected astrocytes is significantly reduced by inducing GSH. Thus, considering the treatment method developed, the success achieved in the use of SPT as therapeutics against neuronal Leishmaniasis lays the groundwork for treatments of other infectious neurodegenerative diseases and enables the design and development of novel preventive and therapeutic methods. It is believed that it lays the groundwork for the molecules that can be an alternative to conventional drug therapies, which are applied in the treatment of Leishmaniasis and neurodegenerative diseases and have difficult patient compliance due to side effects.

The application belongs to the technical field of organic synthesis chemistry, and particularly relates to an azido tellurium ether derivative and a preparation method and application thereof. In an organic solvent, an olefin, ditelluride and azidotrimethylsilane are used as raw materials, and a stirring reaction is carried out under the presence of a photocatalyst and under the condition of visible light irradiation to obtain the azido tellurium ether derivative. The method has mild reaction conditions, simple operation, high yield and good functional group compatibility, and conforms to the principle of green chemistry. Meanwhile, the azido tellurium ether derivative provided by the application has good inhibitory activity on Leishmania, which provides a drug lead compound for the development of a new type of antiparasitic drug, and has important significance for the prevention and / or treatment of Leishmaniasis.

The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.